MICVO Shows Phase I Activity in Recurrent Head and Neck Cancer
Pyxis Oncology reported updated Phase I monotherapy data for micvotabart pelidotin, or MICVO, in second-line or later recurrent or metastatic head and neck squamous-cell carcinoma. Among 33 efficacy-evaluable patients treated at 5.4 mg/kg every…
